Bnp Paribas Asset Management Holding S.A. Arcus Biosciences, Inc. Transaction History
Bnp Paribas Asset Management Holding S.A.
- $40.3 Billion
- Q4 2024
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 1,521,784 shares of RCUS stock, worth $18.3 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
1,521,784
Previous 931,048
63.45%
Holding current value
$18.3 Million
Previous $14.2 Million
59.17%
% of portfolio
0.06%
Previous 0.04%
Shares
15 transactions
Others Institutions Holding RCUS
# of Institutions
201Shares Held
51.1MCall Options Held
266KPut Options Held
171K-
Black Rock Inc. New York, NY9.76MShares$117 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.39MShares$64.7 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.48MShares$41.7 Million0.48% of portfolio
-
State Street Corp Boston, MA3.01MShares$36.1 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.44MShares$29.2 Million0.1% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $866M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...